Back to the future: Mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach

Cancer Prevention Research

Volumn 4, Issue 5, 2011, Pages 628-632

  Meyskens Jr , Frank L ^a,b   Gerner, Eugene W ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; EFLORNITHINE; IMATINIB; K RAS PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RETINOL ACETATE; RETROVIRUS VECTOR; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SULINDAC; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADVANCED CANCER; BREAST CANCER; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG TARGETING; GENE MUTATION; HUMAN; LUNG CARCINOGENESIS; MELANOMA; METASTASIS; NONHUMAN; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUESTIONNAIRE; REVIEW; VIRAL GENE DELIVERY SYSTEM;

APOPTOSIS; BIOMIMETICS; GENES, LETHAL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MITOCHONDRIAL PROTEINS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79955831572     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0162     Document Type: Review

References (23)

1. Sporn MB. Combination chemoprevention of cancer. Nature 1980;287:107-8. (Pubitemid 11227678)
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70. (Pubitemid 26358996)
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7. (Pubitemid 32267972)
4. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
5. Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, Leszczyniecka M, et al. Validating cancer drug targets. Nature 2006;441:451-6. (Pubitemid 44050140)
6. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Bio 2006;2:689-700. (Pubitemid 44764211)
7. Nijman SM. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett 2011;585:1-6.
8. Huang S, Ren X, Wang L, Zhang L, Wu X. Lung cancer chemoprevention by induction of synthetic lethality in mutant-KRAS premalignant cells in vitro and in vivo. Cancer Prev Res 2011;4:666-73.
9. Bender A, Pringle JR. Use of a screen for synthetic lethal and multicopy suppressed mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisae. Mol Cell Biol 1991;11:1295-305. (Pubitemid 21895485)
10. Hartwell L, Szankasi P, Roberts C, Murray AW, Friend SH. Integrated genetic approaches into the discovery of anticancer drugs. Science 1997;278:1064-8. (Pubitemid 27517876)
11. Dunstan HM, Ludlow C, Goehle S, Cronk M, Szankasi P, Evans DR, et al. Cell-based assays for identification of novel double-strand break-inducing agents. J Natl Cancer Inst 2002;94:88-94. (Pubitemid 34121287)
12. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 2001;19:940-5. (Pubitemid 32947572)
13. Einav Y, Shistik E, Shenfeld M, Melton DW, Canaani D. Replication and episomal maintenance of Epstein-Barr virus-based vectors in mouse embryonal fibroblasts enable synthetic lethality screens. Mol Cancer Therapy 2003;2:1121-8.
14. Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98.
15. Zhang L, Ren X, Alt E, Bai X, Huang S, Xu Z, et al. Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature 2010;464:1058-61.
16. Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A. Searching for synthetic lethality in cancer. Curr Opin Genet Dev 2011;21:34-41.
17. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
18. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
19. Meyskens FL, Curt GC, Brenner DE, Gordon G, Herberman RB, Finn O, et al. Regulatory approval of cancer risk-reducing (chemoprevention) drugs: moving what we have learned into the clinic. Cancer Prev Res 2011;4:311-23.
20. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res 2010;3:696-706.
21. Vogel VG. Tipping the balance for the primary prevention of breast cancer. J Natl Cancer Inst 2010;102:1683-5.
22. Meyskens FL, McLaren CE. Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? J Natl Cancer Inst 2010;102:1815-7.
23. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-8.